Patents by Inventor Michel Marie Francois Janicot

Michel Marie Francois Janicot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODIFIED POLY(PROPYLENE-IMINE) DENDRIMERS AND THEIR USE AS TRANSFECTION AGENTS FOR AMIONIC BIOACTIVE FACTORS ( as amended
    Publication number: 20100298403
    Abstract: The present invention is concerned with modified poly-(propylene imine) dendrimers, comprising cationic internal ammonium groups and external non-toxic endgroups, pharmaceutical compositions comprising said dendrimers, methods for the production of said dendrimers and their use as transfections agents for anionic bioactive therapeutic factors, for use in gene therapy, in particular for the treatment of cancer. The modified poly-(propylene imine) dendrimer of generation 1, 2, 3, 4 or 5, also comprising incomplete dendrimers and mixtures thereof, comprising external end groups and internal amine functions are characterized in that: (a) substantially all external endgroups are groups of formula (I) ?wherein R is a radical selected from the group of C1-10alkyl, polyethylene glycol radical and polyethylene glycol gallyl radical; and (b) substantially all internal amine functions are quaternary cationic ammonium functions.
    Type: Application
    Filed: July 5, 2006
    Publication date: November 25, 2010
    Applicant: JANSSEN PHARMACEUTICA N.V.
    Inventors: Frederik Tack, Henricus Marie Janssen, Egbert Willem Meijer, Michel Marie Francois Janicot, Marcus Eli Brewster
  • species that produces a bafilomycin-like metabolite
    Patent number: 7803600
    Abstract: The invention provides a compound of formula (I) and pharmaceutically acceptable salts thereof. Processes for the isolating of this bafilomycin metabolite from a novel Micromonospora species, pharmaceutical compositions containing this metabolite and methods of treatment using said metabolite are also described.
    Type: Grant
    Filed: March 12, 2007
    Date of Patent: September 28, 2010
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Jacobus Alphonsus Josephus Van Dun, Walter Boudewijn Leopold Wouters, Michel Marie François Janicot, Ursula Maria Mocek, Jodi Ann Laakso
  • HISTONE DEACETYLASE INHIBITORS WITH COMBINED ACTIVITY ON CLASS-I AND CLASS-IIB HISTONE DEACETYLASES IN COMBINATION WITH PROTEASOME INHIBITORS
    Publication number: 20090312284
    Abstract: The present invention is concerned with combinations of a proteasome inhibitor and a histone deacetylase inhibitor with combined activity on class-I and class-IIb histone deacetylases, for inhibiting the growth of tumor cells, useful in the treatment of cancer.
    Type: Application
    Filed: September 11, 2007
    Publication date: December 17, 2009
    Inventors: Janine Arts, Peter Willem Jan Hellemans, Michel Marie Francois Janicot, Martin John Page
  • COMBINATIONS OF CLASS-I SPECIFIC HISTONE DEACETYLASE INHIBITORS WITH PROTEASOME INHIBITORS
    Publication number: 20090270419
    Abstract: The present invention is concerned with combinations of a proteasome inhibitor and a class-I specific histone deacetylase inhibitor for inhibiting the growth of tumor cells, useful in the treatment of cancer.
    Type: Application
    Filed: September 11, 2007
    Publication date: October 29, 2009
    Inventors: Janine Arts, Peter Willem Jan Hellemans, Michel Marie Francois Janicot, Martin John Page
  • USE OF MTKI 1 FOR TREATING OR PREVENTING BONE CANCER
    Publication number: 20080213275
    Abstract: The present invention is concerned with the finding that the macrocyclic quinazoline derivative 4,6-ethanediylidenepyrimido[4,5-b][6,1,12]benzoxadiazacyclo-pentadecine, 17-bromo-8,9,10,11,12,13,14,19-octahydro-20-methoxy-13-methyl-, described as compound 22 in PCT publication WO2004/105765, is useful in the manufacture of a medicament for the treatment or prevention of bone cancers and methods for killing bone cancer cells, including osteosarcomas, chondrosarcomas, myeloma bone disease and osteolytic bone metastases from other primary sites. It accordingly provides methods for treating, preventing, delaying or mitigating bone cancer, or for preventing and treating of bone loss associated with cancer metastases.
    Type: Application
    Filed: October 19, 2007
    Publication date: September 4, 2008
    Inventors: Eddy Jean Edgard FREYNE, Michel Marie Francois Janicot, Theo Frans Meert, Timothy Pietro Suren Perera
  • USE OF MTKI 1 FOR TREATING OR PREVENTING BRAIN CANCER
    Publication number: 20080153853
    Abstract: The present invention is concerned with the finding that some the macrocyclic quinazoline derivative 4,6-ethanediylidenepyrimido[4,5-b][6,1,12]benzoxadiazacyclo-pentadecine, 17-bromo-8,9,10,11,12,13,14,19-octahydro-20-methoxy-13-methyl-, described as compound 22 in PCT publication W02004/105765, is useful in the manufacture of a medicament for the treatment or prevention of a primary brain cancer or brain metastasis. It accordingly provides methods for treating, preventing, delaying or mitigating brain cancer, or for preventing or slowing proliferation of cells of brain origin.
    Type: Application
    Filed: October 19, 2007
    Publication date: June 26, 2008
    Inventors: Eddy Jean Edgard FREYNE, Michel Marie Francois Janicot, Martin John Page, Timothy Pietro Suren Perera
  • Bafilomycin-like metabolite from a novel species
    Patent number: 7214705
    Abstract: The invention provides a compound of formula (I) and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: June 30, 2003
    Date of Patent: May 8, 2007
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Jacobus Alphonsus Josephus Van Dun, Walter Boudewijn Leopold Wouters, Michel Marie François Janicot, Ursula Maria Mocek, Jodi Ann Laakso